The association of oestrogen receptor α-haplotypes with cardiovascular risk factors in the British Women's Heart and Health Study
Open Access
- 21 March 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 27 (13) , 1597-1604
Abstract
Aims One previous study among women with established coronary heart disease found a gene–treatment interaction between the oestrogen receptor gene (ESR1) and hormone replacement in their association with high density lipoprotein cholesterol (HDL-c). We aimed to replicate these findings in a general population sample. Methods and results Cross-sectional associations were assessed in a study of 3404 women from 23 towns across Britain who were aged 60–79 at the time of assessment and were described as white by the examining nurse. Women with the T-A haplotype [constructed from two single nucleotide polymorphisms (SNPs) in the first intron of ESR1: c454-397T>C (rs2234693) and c454-351A>G (rs9340799)], which was predicted to be associated with reduced oestrogen response, were more likely to have been past [per haplotype odds ratio 1.16 (95% CI 1.01, 1.33), P = 0.02] or to be current users [per haplotype odds ratio 1.19 (95% CI 0.99, 1.42), P = 0.05] of hormone replacement. However, there was no association between haplotype or either SNP and HDL-c or other cardiovascular disease risk factors and no statistical evidence of an interaction between hormone replacement use and haplotype or either SNP with respect to HDL-c or any other cardiovascular disease risk factors. Conclusion Women with the T-A haplotype are more likely to use hormone replacement. However, genotyping of ESR1 rs2234693 or rs9340799 in post-menopausal women to tailor hormone replacement is unlikely to markedly improve cardiovascular risk.Keywords
This publication has 38 references indexed in Scilit:
- Socioeconomic Position and Hormone Replacement Therapy Use: Explaining the Discrepancy in Evidence From Observational and Randomized Controlled TrialsAmerican Journal of Public Health, 2004
- Commentary: Hormones and heart disease: do trials and observational studies address different questions?International Journal of Epidemiology, 2004
- Commentary: The hormone replacement-coronary heart disease conundrum: is this the death of observational epidemiology?International Journal of Epidemiology, 2004
- Understanding the Divergent Data on Postmenopausal Hormone TherapyNew England Journal of Medicine, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Genomic and nongenomic effects of estrogen in the vasculatureThe American Journal of Cardiology, 2002
- Production and Actions of EstrogensNew England Journal of Medicine, 2002
- The Protective Effects of Estrogen on the Cardiovascular SystemNew England Journal of Medicine, 1999
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidencePreventive Medicine, 1991